江中药业_ 2024 年业绩非交易路演要点

March 30, 2025 04:09 PM GMT Jiangzhong Pharmaceutical Co. Ltd. | Asia Pacific 2024 Results NDR Takeaways Key Takeaways Although earnings have been volatile since Covid-19 ended, return metrics are still among the best for TCMs: 2024 revenue fell 2.6% and earnings rose 9.7% vs. 2023 (pre-announced in February note). Sales of its over-the-counter, prescription, and consumer health segments were +7.1%, -3.5%, and -47.3% vs. 2023. Thus, gains in the OTC segment continued to be offset by losses in the other two. ...